Answer

No, you should not combine caffeine with esketamine without direct medical supervision. This combination is flagged as a critical interaction that may compromise safety or treatment efficacy.

Evidence Assessment

Quality Score: 40 (Tier C - Limited Evidence) The evidence for this specific interaction is based on pharmacological database records (DDInter 2.0) rather than a large body of randomized controlled trials. While the interaction is flagged as critical, the lack of specific clinical trial data on the synergy between these two substances limits the ability to quantify the exact risk.

Clinical Evidence

The interaction between caffeine and esketamine is identified as a critical concern within the DDInter 2.0 database. From a pharmacological perspective, esketamine is an NMDA receptor antagonist used for treatment-resistant depression, often associated with transient increases in blood pressure and heart rate. Caffeine, a methylxanthine, acts as an adenosine receptor antagonist and stimulant, which also increases heart rate and blood pressure.

The primary clinical concern is the additive effect on the cardiovascular system. Because esketamine can cause acute hypertensive responses during and immediately after administration, the addition of a stimulant like caffeine may exacerbate these effects, potentially leading to severe hypertension or tachycardia.

Practical Guidance

Due to the critical severity of this interaction, the following guidance applies: * Avoidance: Patients scheduled for esketamine administration should avoid high doses of caffeine or caffeine-containing energy drinks prior to and during the treatment window. * Monitoring: If caffeine intake has occurred, clinicians must closely monitor blood pressure and heart rate before and after the esketamine dose. * Population Risk: Individuals with pre-existing hypertension, cardiovascular disease, or anxiety disorders are at higher risk for adverse synergistic effects.

Safety & Interactions

Contraindication: NO (Avoid without provider consultation)

• Drug Class/Mechanism: Caffeine (Methylxanthine/Stimulant) and Esketamine (NMDA Receptor Antagonist). The interaction is likely additive regarding sympathomimetic activity (increased heart rate and blood pressure).
• Clinical Management: Patients should disclose all caffeine intake to their healthcare provider. If a patient is experiencing hypertensive crisis or tachycardia following administration, caffeine should be strictly prohibited.
• High-Risk Populations:
  • Cardiovascular Disease: High risk of exacerbating hypertension.
  • Elderly: Increased sensitivity to stimulant-induced tachycardia.
  • Anxiety/Panic Disorders: Potential for increased agitation or panic symptoms when combining a dissociative anesthetic with a stimulant.

Source: DDInter 2.0 (ddinter.scbdd.com)